Skip to Content

Merck Invests in RNA Startup to Target Cancer

If it works, mRNA therapy could provide a simple way to create customized cancer vaccines.
July 5, 2016

Pharmaceutical giant Merck has announced a $200 million licensing agreement with Moderna Therapeutics, a startup based in Cambridge, Massachusetts, that is developing therapies based on RNA. Merck wants to combine its expertise in cancer immunotherapy with Moderna’s personalized cancer vaccines so that the two treatments together can more effectively target cancer.

Moderna hopes to have its tailored cancer vaccines ready for clinical trials in 2017. The company’s novel therapeutics are essentially modified molecules of messenger RNA, or mRNA, which translates the genetic code of DNA into proteins. Rearranging the nucleotides, or letters, in mRNA allows Moderna to create antibodies and other proteins that are useful in therapies for a wide range of conditions.

Theoretically, therapeutic mRNA should allow for the production of virtually any protein in the body. But if it sounds simple, there’s a reason it didn’t gain traction before. If straight mRNA is injected into the bloodstream, the body attacks it in an immune reaction, mistaking it for a virus. Moderna’s treatments overcome this challenge by swapping two of the mRNA letters for natural analogues that don’t trigger a viral immune response.

There are several other companies with similar mRNA-based therapeutics in the works. Shire announced work on using mRNA for a cystic fibrosis treatment in 2014, but it has remained silent on the development ever since. And the German biotech company Ethris is working on mRNA therapy for rare diseases.

Most of the competition in RNA therapy comes from companies working with a different technology: RNA interference, or RNAi, which can block the activity of naturally occurring mRNA. The idea is to halt the production of harmful proteins or the growth of cancer cells. Alnylam, also based in Cambridge, Massachusetts, has two RNAi therapies in late-stage human trials and several more in early clinical testing.

Keep Reading

Most Popular

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

biomass with Charm mobile unit in background
biomass with Charm mobile unit in background

Inside Charm Industrial’s big bet on corn stalks for carbon removal

The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.

AGI is just chatter for now concept
AGI is just chatter for now concept

The hype around DeepMind’s new AI model misses what’s actually cool about it

Some worry that the chatter about these tools is doing the whole field a disservice.

Peter Reinhardt
Peter Reinhardt

How Charm Industrial hopes to use crops to cut steel emissions

The startup believes its bio-oil, once converted into syngas, could help clean up the dirtiest industrial sector.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.